Eliminating schistosomes through vaccination: What are the best immune weapons?

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Fonseca, Cristina Toscano ^a,b   Oliveira, Sergio Costa ^b   Alves, Clarice Carvalho ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Effector mechanisms; Immune response; Protective immunity; Schistosome vaccine; Schistosomiasis

Indexed keywords

ANTIBODY; CALPAIN; CYTOKINE; FATTY ACID BINDING PROTEIN; GLUTATHIONE TRANSFERASE; SH28 GLUTATHIONE TRANSFERASE; SM14; SM28 GLUTATHIONE TRANSFERASE; SM29; SMP 80; TETRASPANIN; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; CELLULAR IMMUNITY; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; LIPID TRANSPORT; NONHUMAN; PARASITE CLEARANCE; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SCHISTOSOMA; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINATION;

EID: 84926630434     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00095     Document Type: Review

References (83)

1. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ (2008) 86:140-6. doi: 10.2471/BLT.07.040089
2. Oliveira SC, Fonseca CT, Cardoso FC, Farias LP, Leite LC. Recent advances in vaccine research against schistosomiasis in Brazil. Acta Trop (2008) 108:256-62. doi:10.1016/j.actatropica.2008.05.023
3. Gryseels B. Schistosomiasis. Infect Dis Clin North Am (2012) 26:383-97. doi:10.1016/j.idc.2012.03.004
4. Jenkins SJ, Hewitson JP, Jenkins GR, Mountford AP. Modulation of the host's immune response by schistosome larvae. Parasite Immunol (2005) 27:385-93. doi:10.1111/j.1365-3024.2005.00789.x
5. Novato-Silva E, Nogueira-Machado JA, Gazzinelli G. Schistosoma mansoni: comparison of the killing effect of granulocytes and complement with or without antibody on fresh and cultured schistosomula in vitro. Am J Trop Med Hyg (1980) 29:1263-7.
6. El Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine (2009) 27:666-73. doi:10.1016/j.vaccine.2008.11.039
7. Inal JM, Sim RB. A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Lett (2000) 470:131-4. doi:10.1016/S0014-5793(00)01304-1
8. Pearce EJ, Hall BF, Sher A. Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor. J Immunol (1990) 144:2751-6.
9. Ramalho-Pinto FJ. Decay accelerating factor (DAF) as the host antigen with protective activity to complement killing of schistosomula. Mem Inst Oswaldo Cruz (1987) 82:213-6. doi:10.1590/S0074-02761987000800037
10. Marikovsky M, Arnon R, Fishelson Z. Proteases secreted by transforming schistosomula of Schistosoma mansoni promote resistance to killing by complement. J Immunol (1988) 141:273-8.
11. Butterworth AE, Sturrock RF, Houba V, Mahmoud AA, Sher A, Rees PH. Eosinophils as mediators of antibody-dependent damage to schistosomula. Nature (1975) 256:727-9. doi:10.1038/256727a0
12. Joseph M, Auriault C, Capron M, Ameisen JC, Pancré V, Torpier G, et al. IgE-dependent platelet cytotoxicity against helminths. Adv Exp Med Biol (1985) 184:23-33. doi:10.1007/978-1-4684-8326-0_2
13. Khalife J, Dunne DW, Richardson BA, Mazza G, Thorne KJ, Capron A, et al. Functional role of human IgG subclasses in eosinophil-mediated killing of schistosomula of Schistosoma mansoni. J Immunol (1989) 142:4422-7.
14. Torben W, Ahmad G, Zhang W, Nash S, Le L, Karmakar S, et al. Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni. Vaccine (2012) 30:6753-8. doi:10.1016/j.vaccine.2012.09.026
15. Balloul JM, Pierce RJ, Grzych JM, Capron A. In vitro synthesis of a 28 kilodalton antigen present on the surface of the schistosomulum of Schistosoma mansoni. Mol Biochem Parasitol (1985) 17:105-14. doi:10.1016/0166-6851(85)90131-8
16. Balloul JM, Grzych JM, Pierce RJ, Capron A. A purified 28,000 dalton protein from Schistosoma mansoni adult worms protects rats and mice against experimental schistosomiasis. J Immunol (1987) 138:3448-53.
17. Swartz JM, Dyer KD, Cheever AW, Ramalingam T, Pesnicak L, Domachowske JB, et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood (2006) 108:2420-7. doi:10.1182/blood-2006-04-015933
18. Jankovic D, Wynn TA, Kullberg MC, Hieny S, Caspar P, James S, et al. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell-and IFN-gamma-dependent effector mechanisms. J Immunol (1999) 162:345-51.
19. Melo TT, Sena IC, Araujo N, Fonseca CT. Antibodies are involved in the protective immunity induced in mice by Schistosoma mansoni schistosomula tegument (Smteg) immunization. Parasite Immunol (2014) 36:107-11. doi:10.1111/pim.12091
20. Torben W, Ahmad G, Zhang W, Siddiqui AA. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models. Vaccine (2011) 29:2262-71. doi:10.1016/j.vaccine.2011.01.040
21. Hewitson JP, Hamblin PA, Mountford AP. In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni. Infect Immun (2007) 75:3539-47. doi:10.1128/IAI.00252-07
22. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol (1998) 16:111-35. doi:10.1146/annurev.immunol.16.1.111
23. Fonseca CT, Brito CF, Alves JB, Oliveira SC. IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine (2004) 22:503-10. doi:10.1016/j.vaccine.2003.07.010
24. Street M, Coulson PS, Sadler C, Warnock LJ, McLaughlin D, Bluethmann H, et al. TNF is essential for the cell-mediated protective immunity induced by the radiation-attenuated schistosome vaccine. J Immunol (1999) 163:4489-94.
25. James SL, Cheever AW, Caspar P, Wynn TA. Inducible nitric oxide synthase-deficient mice develop enhanced type 1 cytokine-associated cellular and humoral immune responses after vaccination with attenuated Schistosoma mansoni cercariae but display partially reduced resistance. Infect Immun (1998) 66:3510-8.
26. Mountford AP, Hogg KG, Coulson PS, Brombacher F. Signaling via interleukin-4 receptor alpha chain is required for successful vaccination against schistosomiasis in BALB/c mice. Infect Immun (2001) 69:228-36. doi:10.1128/IAI.69.1.228-236.2001
27. El Ridi R, Tallima H. Vaccine-induced protection against murine schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines. J Parasitol (2013) 99:194-202. doi:10.1645/GE-3186.1
28. Wilson MS, Cheever AW, White SD, Thompson RW, Wynn TA. IL-10 blocks the development of resistance to re-infection with Schistosoma mansoni. PLoS Pathog (2011) 7:e1002171. doi:10.1371/journal.ppat.1002171
29. Wen X, He L, Chi Y, Zhou S, Hoellwarth J, Zhang C, et al. Dynamics of Th17 cells and their role in Schistosoma japonicum infection in C57BL/6 mice. PLoS Negl Trop Dis (2011) 5:e1399. doi:10.1371/journal.pntd.0001399
30. Zhou Y, Zhang H, Sun XJ, Zheng D, Liang YJ, Luo J, et al. Murine CD8(+)T cell cytotoxicity against schistosomula induced by inoculation of schistosomal 22.6/26GST coupled sepharose 4B beads. Vaccine (2012) 30:2440-7. doi:10.1016/j.vaccine.2012.01.068
31. Coulson PS, Wilson RA. Examination of the mechanisms of pulmonary phase resistance to Schistosoma mansoni in vaccinated mice. Am J Trop Med Hyg (1988) 38:529-39.
32. Coulson PS. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine? Adv Parasitol (1997) 39:271-336. doi:10.1016/S0065-308X(08)60048-2
33. Oswaldo Cruz Foundation. Study to evaluate the safety of the vaccine prepared sm14 against schistosomiasis. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) (2000). Available from: http://clinicaltrials.gov/ct2/show/study/NCT01154049
34. Riveau G, Deplanque D, Remoué F, Schacht AM, Vodougnon H, Capron M, et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis (2012) 6:e1704. doi:10.1371/journal.pntd.0001704
35. Curti E, Kwityn C, Zhan B, Gillespie P, Brelsford J, Deumic V, et al. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother (2013) 9:2342-50. doi:10.4161/hv.25787
36. Taylor JB, Vidal A, Torpier G, Meyer DJ, Roitsch C, Balloul JM, et al. The glutathione transferase activity and tissue distribution of a cloned Mr28K protective antigen of Schistosoma mansoni. EMBO J (1988) 7:465-72.
37. Liu JL, Fontaine J, Capron A, Grzych JM. Ultrastructural localization of Sm28 GST protective antigen in Schistosoma mansoni adult worms. Parasitology (1996) 113:377-91. doi:10.1017/S003118200006652X
38. Boulanger D, Reid GD, Sturrock RF, Wolowczuk I, Balloul JM, Grezel D, et al. Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni. Parasite Immunol (1991) 13:473-90. doi:10.1111/j.1365-3024.1991.tb00545.x
39. Grezel D, Capron M, Grzych JM, Fontaine J, Lecocq JP, Capron A. Protective immunity induced in rat schistosomiasis by a single dose of the Sm28GST recombinant antigen: effector mechanisms involving IgE and IgA antibodies. Eur J Immunol (1993) 23:454-60. doi:10.1002/eji.1830230223
40. Kremer L, Riveau G, Baulard A, Capron A, Locht C. Neutralizing antibody responses elicited in mice immunized with recombinant bacillus Calmette-Guérin producing the Schistosoma mansoni glutathione S-transferase. J Immunol (1996) 156:4309-17.
41. Dupré L, Poulain-Godefroy O, Ban E, Ivanoff N, Mekranfar M, Schacht AM, et al. Intradermal immunization of rats with plasmid DNA encoding Schistosoma mansoni 28 kDa glutathione S-transferase. Parasite Immunol (1997) 19:505-13. doi:10.1046/j.1365-3024.1997.d01-163.x
42. Pancré V, Wolowczuk I, Bossus M, Gras-Masse H, Guerret S, Delanoye A, et al. Evaluation of the effect of Sm28GST-derived peptides in murine hepatosplenic schistosomiasis: interest of the lipopeptidic form of the C-terminal peptide. Mol Immunol (1994) 31:1247-56. doi:10.1016/0161-5890(94)90075-2
43. Pancre V, Wolowczuk I, Guerret S, Copin MC, Delanoye A, Capron A, et al. Protective effect of rSm28GST-specific T cells in schistosomiasis: role of gamma interferon. Infect Immun (1994) 62:3723-30.
44. Dupré L, Kremer L, Wolowczuk I, Riveau G, Capron A, Locht C. Immunostimulatory effect of IL-18-encoding plasmid in DNA vaccination against murine Schistosoma mansoni infection. Vaccine (2001) 19:1373-80. doi:10.1016/S0264-410X(00)00363-7
45. Capron A, Dessaint JP, Capron M, Ouma JH, Butterworth AE. Immunity to schistosomes: progress toward vaccine. Science (1987) 238:1065-72. doi:10.1126/science.3317823
46. Boulanger D, Warter A, Trottein F, Mauny F, Brémond P, Audibert F, et al. Vaccination of patas monkeys experimentally infected with Schistosoma haematobium using a recombinant glutathione S-transferase cloned from S. mansoni. Parasite Immunol (1995) 17:361-9. doi:10.1111/j.1365-3024.1995.tb00903.x
47. Boulanger D, Warter A, Sellin B, Lindner V, Pierce RJ, Chippaux JP, et al. Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge. Vaccine (1999) 17:319-26. doi:10.1016/S0264-410X(98)00202-3
48. Moser D, Tendler M, Griffiths G, Klinkert MQ. A 14-kDa Schistosoma mansoni polypeptide is homologous to a gene family of fatty acid binding proteins. J Biol Chem (1991) 266:8447-54.
49. Furlong ST. Unique roles for lipids in Schistosoma mansoni. Parasitol Today (1991) 7:59-62. doi:10.1016/0169-4758(91)90192-Q
50. Meyer F, Meyer H, Bueding E. Lipid metabolism in the parasitic and free-living flatworms, Schistosoma mansoni and Dugesia dorotocephala. Biochim Biophys Acta (1970) 210:257-66. doi:10.1016/0005-2760(70)90170-0
51. Brito CF, Oliveira GC, Oliveira SC, Street M, Riengrojpitak S, Wilson RA, et al. Sm14 gene expression in different stages of the Schistosoma mansoni life cycle and immunolocalization of the Sm14 protein within the adult worm. Braz J Med Biol Res (2002) 35:377-81. doi:10.1590/S0100-879X2002000300014
52. Tendler M, Brito CA, Vilar MM, Serra-Freire N, Diogo CM, Almeida MS, et al. A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Proc Natl Acad Sci U S A (1996) 93:269-73. doi:10.1073/pnas.93.1.269
53. Fonseca CT, Cunha-Neto E, Goldberg AC, Kalil J, de Jesus AR, Carvalho EM, et al. Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis. Microbes Infect (2005) 7:204-12. doi:10.1016/j.micinf.2004.10.012
54. Garcia TC, Fonseca CT, Pacifico LG, Durães Fdo V, Marinho FA, Penido ML, et al. Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice. Acta Trop (2008) 106:162-7. doi:10.1016/j.actatropica.2008.03.003
55. Fonseca CT, Pacífico LG, Barsante MM, Rassi T, Cassali GD, Oliveira SC. Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone. Microbes Infect (2006) 8:2509-16. doi:10.1016/j.micinf.2006.06.008
56. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J (1997) 11:428-42.
57. Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, Wilson A. The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction. Proteomics (2006) 6:1471-82. doi:10.1002/pmic.200500368
58. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol (2005) 6:801-11. doi:10.1038/nrm1736
59. Hemler ME. Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov (2008) 7:747-58. doi:10.1038/nrd2659
60. Tran MH, Freitas TC, Cooper L, Gaze S, Gatton ML, Jones MK, et al. Suppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in impaired tegument turnover. PLoS Pathog (2010) 6:e1000840. doi:10.1371/journal.ppat.1000840
61. Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med (2006) 12:835-40. doi:10.1038/nm1430
62. Pearson MS, Pickering DA, McSorley HJ, Bethony JM, Tribolet L, Dougall AM, et al. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis (2012) 6:e1564. doi:10.1371/journal.pntd.0001564
63. Cai P, Bu L, Wang J, Wang Z, Zhong X, Wang H. Molecular characterization of Schistosoma japonicum tegument protein tetraspanin-2: sequence variation and possible implications for immune evasion. Biochem Biophys Res Commun (2008) 372:197-202. doi:10.1016/j.bbrc.2008.05.042
64. Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, et al. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta (1993) 1181:37-44. doi:10.1016/0925-4439(93)90087-H
65. Silva EE, Clarke MW, Podesta RB. Characterization of a C3 receptor on the envelope of Schistosoma mansoni. J Immunol (1993) 151:7057-66.
66. Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis (2010) 14:e781-7. doi:10.1016/j.ijid.2010.02.2266
67. Zhang R, Yoshida A, Kumagai T, Kawaguchi H, Maruyama H, Suzuki T, et al. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun (2001) 69:386-91. doi:10.1128/IAI.69.1.386-391.2001
68. Siddiqui AA, Siddiqui BA, Ganley-Leal L. Schistosomiasis vaccines. Hum Vaccin (2011) 7:1192-7. doi:10.4161/hv.7.11.17017
69. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine (2003) 21:2882-9. doi:10.1016/S0264-410X(03)00159-2
70. Siddiqui AA, Pinkston JR, Quinlin ML, Kavikondala V, Rewers-Felkins KA, Phillips T, et al. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite (2005) 12:3-8. doi:10.1051/parasite/2005121003
71. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun (2003) 71:3844-51. doi:10.1128/IAI.71.7.3844-3851.2003
72. Karmakar S, Zhang W, Ahmad G, Alam MU, Winn R, Torben W, et al. Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni. Hum Vaccin Immunother (2014) 10:640-7. doi:10.4161/hv.27576
73. Cardoso FC, Pinho JM, Azevedo V, Oliveira SC. Identification of a new Schistosoma mansoni membrane-bound protein through bioinformatic analysis. Genet Mol Res (2006) 5:609-18.
74. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, de Melo AL, et al. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis (2008) 2:e308. doi:10.1371/journal.pntd.0000308
75. Pinheiro CS, Ribeiro AP, Cardoso FC, Martins VP, Figueiredo BC, Assis NR, et al. A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice. Parasite Immunol (2014) 36:303-12. doi:10.1111/pim.12118
76. Ewaisha RE, Bahey-El-Din M, Mossallam SF, Amer EI, Aboushleib HM, Khalil AM. Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection. Exp Parasitol (2014) 145:51-60. doi:10.1016/j.exppara.2014.07.010
77. Correa-Oliveira R, Pearce EJ, Oliveira GC, Golgher DB, Katz N, Bahia LG, et al. The human immune response to defined immunogens of Schistosoma mansoni: elevated antibody levels to paramyosin in stool-negative individuals from two endemic areas in Brazil. Trans R Soc Trop Med Hyg (1989) 83:798-804. doi:10.1016/0035-9203(89)90334-9
78. Brito CF, Caldas IR, Coura Filho P, Correa-Oliveira R, Oliveira SC. CD4+ T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14KDA Schistosoma mansoni fatty acid-binding protein. Scand J Immunol (2000) 51:595-601. doi:10.1046/j.1365-3083.2000.00710.x
79. Brito CF, Fonseca CT, Goes AM, Azevedo V, Simpson AJ, Oliveira SC. Human IgG1 and IgG3 recognition of Schistosoma mansoni 14kDa fatty acid-binding recombinant protein. Parasite Immunol (2000) 22:41-8.
80. Cardoso FC, Pacífico RN, Mortara RA, Oliveira SC. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol (2006) 144:382-91. doi:10.1111/j.1365-2249.2006.03081.x
81. Zhang R, Suzuki T, Takahashi S, Yoshida A, Kawaguchi H, Maruyama H, et al. Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum. Parasitol Int (2000) 48:232-42. doi:10.1016/S1383-5769(99)00024-0
82. Al-Sherbiny M, Osman A, Barakat R, El Morshedy H, Bergquist R, Olds R. In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Trop (2003) 88:117-30. doi:10.1016/S0001-706X(03)00195-5
83. Grzych JM, Grezel D, Xu CB, Neyrinck JL, Capron M, Ouma JH, et al. IgA antibodies to a protective antigen in human Schistosomiasis mansoni. J Immunol (1993) 150:527-35.